Protected percutaneous coronary intervention - a new road for success in treating complex patients.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 27625681)

Published in Postepy Kardiol Interwencyjnej on August 19, 2016

Authors

Fadi Al-Rashid1, Heike A Hildebrandt1, Philipp Kahlert1

Author Affiliations

1: Department of Cardiology, West German Heart and Vascular Center, Essen University Hospital, University Duisburg-Essen, Essen, Germany.

Articles cited by this

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17

Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet (2013) 4.34

A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation (2012) 2.08

2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.04

Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT ΙΙ study. Catheter Cardiovasc Interv (2013) 1.50

2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv (2011) 1.13

Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). Am J Cardiol (2014) 1.11

How should I treat a significant and inoperable left main coronary atherosclerotic disease (LMCAD) in the setting of a severely depressed left ventricular systolic function and severe aorto-iliac atherosclerotic disease? EuroIntervention (2015) 0.82